Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies for cancer, has highlighted recent achievements in its pipeline…
Pulse Biosciences Appoints Paul LaViolette as CEO Pulse Biosciences, Inc. (Nasdaq: PLSE), a leader in bioelectric medicine utilizing its cutting-edge Nanosecond Pulsed Field Ablation™ (nano-PFA™) technology, today announces the appointment of Paul A. LaViolette, the current Co-Chairman of the Board,…
Modivcare Secures $105 Million in Financing and Positions for Future Growth Modivcare Inc. (Nasdaq: MODV), a technology-enabled healthcare services company focused on integrated supportive care solutions, today announced several key initiatives to support its future growth. The company has secured…
Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics Marea Therapeutics, a clinical-stage biotechnology company focused on developing next-generation treatments for cardio-endocrine diseases, shared important updates on its progress as it prepares for the upcoming…
Heidelberg Engineering’s ANTERION® Gets FDA Clearance for Epithelial Thickness Module Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, has announced the FDA clearance of its Epithelial Thickness Module, now available exclusively through the ANTERION® Cornea App.…
Clinical Progress and Business Updates in Oncology Pipeline Reported by Nimbus Therapeutics Nimbus Therapeutics, a biotechnology company leveraging its advanced computational drug discovery engine to develop breakthrough medicines, today announced significant progress in its clinical oncology pipeline. Additionally, the company…
Reports Complete Response in First Infant with ECUR-506 for OTC Deficiency, iECURE iECURE, Inc., a gene-editing company focused on developing in vivo gene insertion therapies for liver disorders, reports promising preliminary findings from the first infant dosed in the ongoing…
Colorectal Cancer: SOTIO Advances SOT109 ADC and Licenses Antibodies from Biocytogen SOTIO Biotech, a clinical-stage biopharmaceutical company owned by the PPF Group, has announced an exciting milestone in the development of its novel antibody-drug conjugate (ADC) candidate, SOT109. The company…
Pharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial Thetis Pharmaceuticals LLC, a clinical-stage company focused on developing TP-317, a pioneering small molecule drug targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis, has…
Appoints Eric Davidson as Chief Commercial Officer Mendaera Inc., a healthcare technology company focused on developing an innovative handheld robotic platform for interventional procedures, appoints Eric Davidson as its first Chief Commercial Officer (CCO). In this newly created role, Davidson…
Cyrus Selects CYR212 as Candidate for IgG-Driven Autoimmune Diseases Cyrus Biotechnology, an AI-driven therapeutics company, announced the selection of CYR212 as its clinical development candidate for chronic IgG-driven autoimmune diseases. CYR212 is a next-generation, engineered Immunoglobulin-G (IgG) protease designed to…
Peanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers Stallergenes Greer, a biopharmaceutical company specializing in allergen immunotherapy (AIT), has announced that the European Commission (EC) has granted approval for the extension of Palforzia® (defatted powder of Arachis…